Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Mid Cap Fund median (32 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 06 Feb 2018 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty Midcap 150 history starts 14 Jan 2019, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | Mahindra Manulife Mid Cap Fund |
|---|---|
| 06 Feb 2018 | ₹100.00 |
| 24 Oct 2018 | ₹94.40 |
| 11 Jul 2019 | ₹100.41 |
| 26 Mar 2020 | ₹86.03 |
| 11 Dec 2020 | ₹126.67 |
| 28 Aug 2021 | ₹182.80 |
| 15 May 2022 | ₹163.64 |
| 29 Jan 2023 | ₹182.32 |
| 16 Oct 2023 | ₹233.80 |
| 02 Jul 2024 | ₹326.05 |
| 19 Mar 2025 | ₹288.56 |
| 03 Dec 2025 | ₹325.74 |
| 20 Aug 2026 | ₹347.47 |
| Metric | Mahindra Manulife · Direct · IDCW NAV ₹32.49 Very High risk ★★★★☆ | Category median Mid Cap Fund · 32 funds |
|---|---|---|
| +8.72% | +6.29% | |
| +17.18% | +14.78% | |
| +14.03% | +13.99% | |
| — | +9.73% | |
| +15.71% | +15.68% | |
| +14.72% | — | |
| +21.25% | +16.53% | |
| +20.46% | +14.94% | |
| — | +12.00% | |
| Risk | ||
| 17.49% | 16.93% | |
| 0.61 | 0.53 | |
| 0.80 | 0.73 | |
| -33.07% | -36.26% | |
| Nifty Midcap 150 | — | |
| -1.00% | -2.10% | |
| 0.98 | 0.97 | |
| 98.0% | 93.0% | |
| 103.5% | 95.9% | |
| 0.75% | 0.95% | |
| ₹4,747Cr | ₹7,889Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹1.00K | — | |
| 72% | 40% | |
| Manish Lodha · 5.7y | — | |
| 06 Feb 2018 | — | |
| 58 | — | |
| 26.0% | — | |
| 1.8% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.